Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies [PDF]
Journal of Ophthalmic & Vision Research, 2021 Purpose: To assess the effect of patient baseline characteristics on the efficacy of ocriplasmin treatment for symptomatic vitreomacular adhesion (VMA) with full-thickness macular hole (FTMH) from phase 3/4 studies.
Brian C. Joondeph +4 more
doaj +3 more sources
Efficacy and Safety of Ocriplasmin Use for Vitreomacular Adhesion and Its Predictive Factors: A Systematic Review and Meta-Analysis [PDF]
Frontiers in Medicine, 2022 Symptomatic vitreomacular adhesion (sVMA) impedes visual acuity and quality. Ocriplasmin is a recombinant protease, which may be injected into the vitreous cavity to treat this condition, yet controversy remains with respect to its effectiveness and ...
Xi Chen +4 more
doaj +4 more sources
Post hoc analysis of ellipsoid zone changes beyond the central subfield in symptomatic vitreomacular adhesion patients from the OASIS trial [PDF]
BMJ Open Ophthalmology, 2021 Background/aims OASIS is a Phase IIIb trial (NCT01429441) assessing long-term outcomes in subjects with symptomatic vitreomacular adhesion (VMA). The purpose of this study is to report on the frequency, severity, location and time course of ellipsoid ...
Michael S Ip +4 more
doaj +2 more sources
Treatment of Symptomatic Vitreomacular Adhesion With Expansile Sulfur Hexafluoride (SF6) Gas [PDF]
Open Ophthalmology Journal, 2017 Dominic M Buzzacco
exaly +2 more sources
Mutational Analysis of Ocriplasmin to Reduce Proteolytic and Autolytic Activity in Pichia pastoris
Biological Procedures Online, 2020 Background Ocriplasmin (Jetrea) is using for the treatment of symptomatic vitreomacular adhesion. This enzyme undergoes rapid inactivation and limited activity duration as a result of its autolytic nature after injection within the eye.
Roghayyeh Baghban +6 more
doaj +1 more source
Senses and Sciences, 2016 Purpose: To evaluate the efficacy and the safety of the enzymatic vitreolysis with a single intravitreal injection of ocriplasmin 125 μg across a group of patients with symptomatic vitreomacular adhesion (sVMA) during 6 months follow up.
Fernanda Pacella +6 more
doaj +1 more source
Clinical Ophthalmology, 2021 Kimberly A Drenser,1 Dante J Pieramici,2,3 Joseph M Gunn,4 Daniel F Rosberger,5 Petra Kozma,6 Mitchell S Fineman,7,8 Luc Duchateau,9 Arshad M Khanani10 1Associated Retinal Consultants P.C., Royal Oak, MI, USA; 2California Retina Consultants, Santa ...
Drenser KA +7 more
doaj
Incidence and prevalence of vitreomacular traction with and without macular hole in Germany
Clinical Ophthalmology, 2019 Jacob Menzler,1 Aljoscha Steffen Neubauer,1,2 Christos Haritoglou,3 Timothy L Jackson4 1Institute for Health- and Pharmacoeconomics/Neubauer Consult, Munich, Germany; 2Private practice, Munich, Germany; 3Herzog Carl Theodor Eye Hospital, Munich, Germany;
Menzler J +3 more
doaj
Patient Related Outcome Measures, 2019 Benedicte Lescrauwaet,1 Koenraad Blot,2 Timothy L Jackson3 1Xintera, Outcomes Research, Ghent, Belgium; 2Xintera, Ghent, Belgium; 3Life Sciences and Medicine, King’s College London, Department of Ophthalmology, King’s College Hospital, London,
Lescrauwaet B, Blot K, Jackson TL
doaj
Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
Clinical Ophthalmology, 2014 Francisco R Stefanini,1–3 Maurício Maia,1 Paulo Falabella,1–3 Marcel Pfister,2,3 Moritz Niemeyer,2 Amir H Kashani,3 Mark S Humayun,3 Michael J Koss2,3,41Retina Division, Department of Ophthalmology and Visual Sciences, Federal ...
Stefanini FR +7 more
doaj